Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Systematic Review
  • Published:

Clinical Research

The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a graded, systematic review and meta-analysis of randomized controlled trials

International Journal of Obesity volume 50, pages 492–506 (2026)Cite this article

Subjects

Abstract

Background

The effects of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels remain inconclusive in individuals with overweight and obesity.

Method

This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the effects of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels. We searched electronic databases, including Scopus, Web of Science, and PubMed, up to September 2025, to identify eligible RCTs.

Results

A total of 23 RCTs, involving 1005 participants, met the inclusion criteria for the meta-analysis. Resveratrol supplementation did not significantly affect body weight (WMD: −1.42 kg; 95% CI: −3.19, 0.35; P = 0.117), body mass index (BMI) (WMD: −0.47 kg/m²; 95% CI: −0.96, 0.01; P = 0.055), fat mass (FM) (WMD: 0.47 kg; 95% CI: −1.75, 2.69; P = 0.679), body fat percentage (BFP) (WMD: −0.88%; 95% CI: −1.91, 0.15; P = 0.094), fat-free mass (FFM) (WMD: 1.42 kg; 95% CI: −1.04, 3.89; P = 0.257), waist-hip ratio (WHR) (WMD: -0.00; 95% CI: −0.01, 0.00; P = 0.436), adiponectin (WMD: 1.84 µg/mL; 95% CI: −2.25, 5.95; P = 0.378), or leptin (WMD: 1.87 ng/mL; 95% CI: −3.84, 7.60; P = 0.521). However, resveratrol supplementation significantly reduced waist circumference (WC) (WMD: −1.93 cm; 95% CI: −3.10, −0.76; P = 0.001). Subgroup analyses revealed significant reductions in body weight and BMI with doses <1000 mg/day, longer interventions (≥12 weeks), and in females. Additionally, FFM increased significantly among participants aged <50 years, and leptin levels were significantly elevated in both sexes.

Conclusion

This meta-analysis showed that resveratrol supplementation did not significantly impact most anthropometric measures and serum leptin and adiponectin in individuals with overweight and obesity. However, it led to a significant reduction in waist circumference.

The PROSPERO registration number: is CRD42024497932.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2: Forest plot of the effect of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels inindividuals with overweight and obesity.
Fig. 3: Funnel plot assessing publication bias for the effect of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels in individuals with overweight and obesity.

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Purnell JQ. Definitions, classification, and epidemiology of obesity. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.

  2. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metab Clin Exp. 2019;92:98–107.

    Article  CAS  PubMed  Google Scholar 

  3. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012;10:22.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rennie KL, Jebb SA. Prevalence of obesity in Great Britain. Obes Rev. 2005;6:11–2.

    Article  CAS  PubMed  Google Scholar 

  5. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804–14.

    Article  PubMed  Google Scholar 

  6. Roth J, Qiang X, Marbán SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obes Res. 2004;12:88s–101s.

    Article  PubMed  Google Scholar 

  7. Trends in adult body-mass index in 200 countries from 1975 to 2014. a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–96.

    Article  Google Scholar 

  8. Melina V, Craig W, Levin SJ Jot Ao N, Dietetics. Position of the Academy of Nutrition and Dietetics: vegetarian diets. 2016;116:1970–80.

  9. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diab Endocrinol. 2025;13:221–62.

    Article  Google Scholar 

  10. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23:770–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zagotta I, Dimova EY, Debatin K-M, Wabitsch M, Kietzmann T, Fischer-Posovszky P. Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue. Front Pharmacol. 2015;6:79.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947–53.

    Article  CAS  PubMed  Google Scholar 

  14. Peri K, Eisenberg M. Review on obesity management: diet, exercise and pharmacotherapy. BMJ Public Health 2024; 2.

  15. Suárez R, Bautista-Valarezo E, Matos A, Calderón P, Fascì-Spurio F, Castano-Jimenez J, et al. Obesity and nutritional strategies: advancing prevention and management through evidence-based approaches. Food Agric Immunol. 2025;36:2491597.

    Article  Google Scholar 

  16. Raiman L, Amarnani R, Abdur-Rahman M, Marshall A, Mani-Babu S. The role of physical activity in obesity: let’s actively manage obesity. Clin Med. 2023;23:311–7.

    Article  Google Scholar 

  17. Kong Y, Yang H, Nie R, Zhang X, Zuo F, Zhang H, et al. Obesity: pathophysiology and therapeutic interventions. Mol Biomed. 2025;6:1–41.

    Article  Google Scholar 

  18. Asbaghi O, Rezaei Kelishadi M, Larky DA, Bagheri R, Amirani N, Goudarzi K, et al. The effects of green tea extract supplementation on body composition, obesity-related hormones and oxidative stress markers: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials. Br J Nutr. 2024;131:1125–57.

    Article  CAS  PubMed  Google Scholar 

  19. Asbaghi O, Sadeghian M, Rahmani S, Mardani M, Khodadost M, Maleki V, et al. The effect of green coffee extract supplementation on anthropometric measures in adults: a comprehensive systematic review and dose-response meta-analysis of randomized clinical trials. Complement Ther Med. 2020;51:102424.

    Article  PubMed  Google Scholar 

  20. Frémont L. Biological effects of resveratrol. Life Sci. 2000;66:663–73.

    Article  PubMed  Google Scholar 

  21. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health–a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011;55:1129–41.

    Article  CAS  PubMed  Google Scholar 

  22. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50:3337–40.

    Article  CAS  PubMed  Google Scholar 

  23. Raj P, Louis XL, Thandapilly SJ, Movahed A, Zieroth S, Netticadan T. Potential of resveratrol in the treatment of heart failure. Life Sci. 2014;95:63–71.

    Article  CAS  PubMed  Google Scholar 

  24. Diaz-Gerevini GT, Repossi G, Dain A, Tarres MC, Das UN, Eynard AR. Beneficial action of resveratrol: How and why? Nutrition. 2016;32:174–8.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang LX, Li CX, Kakar MU, Khan MS, Wu PF, Amir RM, et al. Resveratrol (RV): a pharmacological review and call for further research. Biomed Pharmacother. 2021;143:112164.

    Article  CAS  PubMed  Google Scholar 

  26. Gu W, Geng J, Zhao H, Li X, Song G. Effects of resveratrol on metabolic indicators in patients with type 2 diabetes: a systematic review and meta-analysis. Int J Clin Pract. 2022;2022:9734738.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharm. 2010;635:1–8.

    Article  CAS  Google Scholar 

  28. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837–43.

    Article  CAS  PubMed  Google Scholar 

  29. Jimoh A, Tanko Y, Ayo JO, Ahmed A, Mohammed A. Resveratrol increases serum adiponectin level and decreases leptin and insulin level in an experimental model of hypercholesterolemia. Pathophysiology. 2018;25:411–7.

    Article  CAS  PubMed  Google Scholar 

  30. Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25:1–18.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Arzola-Paniagua MA, García-Salgado López ER, Calvo-Vargas CG, Guevara-Cruz M. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: a randomized controlled trial. Obesity. 2016;24:1454–63.

    Article  CAS  PubMed  Google Scholar 

  32. Walker JM, Eckardt P, Aleman JO, da Rosa JC, Liang Y, Iizumi T, et al. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: a pilot randomized, placebo-controlled clinical trial. J Clin Transl Res. 2018;4:122–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Batista-Jorge GC, Barcala-Jorge AS, Silveira MF, Lelis DF, Andrade JMO, de Paula AMB, et al. Oral resveratrol supplementation improves metabolic syndrome features in obese patients submitted to a lifestyle-changing program. Life Sci. 2020;256:117962.

    Article  CAS  PubMed  Google Scholar 

  34. Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014;57:181–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Abdollahi S, Salehi-Abargouei A, Toupchian O, Sheikhha MH, Fallahzadeh H, Rahmanian M, et al. The effect of resveratrol supplementation on cardio-metabolic risk factors in patients with type 2 diabetes: a randomized, double-blind controlled trial. Phytother Res. 2019;33:3153–62.

    Article  CAS  PubMed  Google Scholar 

  36. Poulsen MK, Nellemann B, Bibby BM, Stødkilde-Jørgensen H, Pedersen SB, Grønbaek H, et al. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diab Obes Metab. 2018;20:2504–9.

    Article  CAS  Google Scholar 

  37. Tabrizi R, Tamtaji OR, Lankarani KB, Akbari M, Dadgostar E, Dabbaghmanesh MH, et al. The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60:375–90.

    Article  CAS  PubMed  Google Scholar 

  38. Delpino FM, Figueiredo LM, Caputo EL, Mintem GC, Gigante DP. What is the effect of resveratrol on obesity? A systematic review and meta-analysis. Clin Nutr ESPEN. 2021;41:59–67.

    Article  PubMed  Google Scholar 

  39. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372.

  40. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.

    Article  PubMed  Google Scholar 

  41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin trials. 1986;7:177–88.

    Article  CAS  PubMed  Google Scholar 

  42. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis, John Wiley & Sons, 2011.

  43. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:1–10.

    Article  Google Scholar 

  44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327:557–60.

    Google Scholar 

  45. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

    Article  PubMed  Google Scholar 

  46. Tobias A. Assessing the influence of a single study in the meta-anyalysis estimate. STATA Tech Bull 1999; 8.

  47. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Edition) 1997; 315:629–34.

  48. Oxman GordonH, Vist A, Kunz G, Falck-Ytter R, Alonso-Coello Y, Schünemann P. H. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–26.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Van der Made SM, Plat J, Mensink RP. Trans-resveratrol supplementation and endothelial function during the fasting and postprandial phase: a randomized placebo-controlled trial in overweight and slightly obese participants. Nutrients 2017; 9.

  51. Timmers S, de Ligt M, Phielix E, van de Weijer T, Hansen J, Moonen-Kornips E, et al. Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial. Diab Care. 2016;39:2211–7.

    Article  CAS  Google Scholar 

  52. de Ligt M, Bergman M, Fuentes RM, Essers H, Moonen-Kornips E, Havekes B, et al. No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial. Am J Clin Nutr. 2020;112:1029–38.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wong RH, Berry NM, Coates AM, Buckley JD, Bryan J, Kunz I, et al. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens. 2013;31:1819–27.

    Article  CAS  PubMed  Google Scholar 

  54. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092–103.e1-6.

    Article  CAS  PubMed  Google Scholar 

  55. Méndez-del Villar M, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG, Lizárraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12:497–501.

    Article  PubMed  Google Scholar 

  56. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95.

    Article  CAS  PubMed  Google Scholar 

  57. Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456–64.

    Article  PubMed  Google Scholar 

  58. Kjær TN, Ornstrup MJ, Poulsen MM, Stødkilde-Jørgensen H, Jessen N, Jørgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102:1642–51.

    Article  PubMed  Google Scholar 

  59. Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diab Obes Metab. 2018;20:1793–7.

    Article  CAS  Google Scholar 

  60. Witte AV, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34:7862–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Asghari S, Asghari-Jafarabadi M, Somi M-H, Ghavami S-M, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr. 2018;37:223–33.

    Article  CAS  PubMed  Google Scholar 

  62. Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res. 2020;90:279–89.

    Article  CAS  PubMed  Google Scholar 

  63. Farzin L, Mansouri E, Salehi S, Baker E, Amirkhizi F, Asghari S. Effects of resveratrol supplementation on serum concentrations of plasminogen activator inhibitor-1, fibroblast growth factor 21, and adiponectin in patients with nonalcoholic fatty liver disease. BMC Nutr. 2025;11:36.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Mahmood WA, Mshimesh BAR, Khazaal FAK, Jasim SY, Mahmood AA. Potential effects of resveratrol on obesity-related nephropathy in Iraqi obese women. J Pharm Sci Res. 2018;10:999–1005.

    CAS  Google Scholar 

  65. Al Nuaimi WAM, Al-Nuaimi AAM. Potential effects of resveratrol on obesity markers of Iraqi women. Eur J Nat Sci Med. 2020;3:70–4.

    Google Scholar 

  66. Mousavi SM, Milajerdi A, Sheikhi A, Kord-Varkaneh H, Feinle-Bisset C, Larijani B, et al. Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. Obes Rev. 2019;20:487–98.

    Article  CAS  PubMed  Google Scholar 

  67. Huang H, Chen G, Liao D, Zhu Y, Pu R, Xue X. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016;17:1329–40.

    Article  CAS  PubMed  Google Scholar 

  68. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–22.

    Article  CAS  PubMed  Google Scholar 

  69. Dal-Pan A, Blanc S, Aujard F Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol. 2010; 10:11.

  70. Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab. 2014;24:2–13.

    Article  CAS  PubMed  Google Scholar 

  71. Eseberri I, Lasa A, Churruca I, Portillo MP. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One. 2013;8:e63918.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One. 2008;3:e2264.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

    Azin Setayesh, Mohammadreza Moradi Baniasadi, Maryam Lahouti & Leila Azadbakht

  2. Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Azin Setayesh & Mohammadreza Moradi Baniasadi

  3. Qods Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Pishva Arzhang

  4. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Leila Azadbakht

  5. Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

    Leila Azadbakht

Authors
  1. Azin Setayesh
    View author publications

    Search author on:PubMed Google Scholar

  2. Pishva Arzhang
    View author publications

    Search author on:PubMed Google Scholar

  3. Mohammadreza Moradi Baniasadi
    View author publications

    Search author on:PubMed Google Scholar

  4. Maryam Lahouti
    View author publications

    Search author on:PubMed Google Scholar

  5. Leila Azadbakht
    View author publications

    Search author on:PubMed Google Scholar

Contributions

AS, PA, and LA designed the study. AS and MMB performed a literature search and data extraction. Data analysis was done by AS, PA. AS and MMB wrote the paper. AS, ML, PA, and LA revised the final version of the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Leila Azadbakht.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Setayesh, A., Arzhang, P., Baniasadi, M.M. et al. The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a graded, systematic review and meta-analysis of randomized controlled trials. Int J Obes 50, 492–506 (2026). https://doi.org/10.1038/s41366-025-01994-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41366-025-01994-0

Search

Advanced search

Quick links